Search

Vepdegestrant

, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. … [A275507, A275508, A275511] It was identified through a targeted medicinal chemistry optimization campaign to act as a next-generation endocrine therapy for breast cancer.

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].

Nelarabine

[A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … not responded to or has relapsed following at least two chemotherapy regimens.

Sodium phosphate, dibasic, unspecified form

Colchicine

Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961. … [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602]

Cerliponase alfa

[L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]

Fennel

Lithium cation

Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. … It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches.

Rexin G

Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for...

Belimumab

[L42630] BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE). … [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.